Learn More
Promega ApoLive-Glo™ Multiplex Assay 
The ApoLive-Glo™ Multiplex Assay measures both the number of viable cells as a marker of cytotoxicity and caspase activation as a marker of apoptosis within a single assay well to determine the mechanism of cell death.
$2,542.08 - $2,542.08
Specifications
| Detection Method | Fluorescence, Luminescence |
|---|---|
| For Use With (Application) | Profile Compounds for Cytotoxic Risk |
Includes: GF-AFC Substrate, Assay Buffer, Caspase-Glo 3/7 Buffer, Caspase-Glo 3/7 Substrate
| Catalog Number | Mfr. No. | Kit Contents | Quantity | Price | Quantity | ||||
|---|---|---|---|---|---|---|---|---|---|
| Catalog Number | Mfr. No. | Kit Contents | Quantity | Price | Quantity | ||||
|
PRG6411
|
Promega
G6411 |
1 x 50 μL GF-AFC substrate, 2 x 10 mL Assay Buffer, 5 x 10 mL Caspase-Glo™ 3/7 Buffer, 5 x 1 bottle Caspase-Glo™ 3/7 substrate | 5 x 10 mL |
Each for $2,542.08
|
|
||||
Description
- Measure Viability and Apoptosis in the Same Sample Well
- Accurately determine mechanism of cell death in less time, with less sample
- Easy to implement using a simple sequential 'add-mix-measure' protocol
- Adaptable to meet various throughput needs
Specifications
| Fluorescence, Luminescence | |
| Profile Compounds for Cytotoxic Risk |
U.S. Patents 7,416,854; 7,553,632 and other patents pending.
U.S. Patents 6,602,677 and 7,241,584, Australian Patents 754312 and 785294 and other patents and patents pending.
U.S. Patents 7,148,030 and 7,384,758, Australian Patent 2003216139 and other patents pending.
The method of recombinant expression of Coleoptera luciferase is covered by U.S. Patents 5,583,024, 5,674,713 and 5,700,673.